FDA Sets PDUFA Date for Investigational Glaucoma Eye Drop

The FDA accepts Nicox’s NDA for an investigational glaucoma drop; Bausch + Lomb provides updates on two key investigational therapies for dry eye and ocular surface pain; and Ocugen doses the first patient in a global phase 3 trial of an investigational gene therapy for geographic atrophy (GA).

Learn more about your ad choices. Visit megaphone.fm/adchoices